Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 5/20 | 0.73 |
| ▸ | PTH1R | Q03431 | 9/20 | 0.73 |
| ▸ | CCKBR | P32239 | 1/20 | 0.71 |
| ▸ | GRPR | P30550 | 1/20 | 0.71 |
| ▸ | ECE1 | P42892 | 1/20 | 0.69 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411571 | 0.94 | PTH1R (0.77) | GLP1RPTH1RCCKBRGRPRECE1 | |
| SCHEMBL30744286 | 0.94 | NR3C1 (0.71) | GLP1RPTH1RCCKBRGRPRECE1 | |
| SCHEMBL29395456 | 0.93 | GLP1R (0.78) | GLP1RPTH1RCCKBRECE1MUS81 | |
| SCHEMBL29357856 | 0.93 | GLP1R (0.77) | GLP1RPTH1RCCKBRECE1MUS81 | |
| SCHEMBL29540128 | 0.92 | GLP1R (0.79) | GLP1RPTH1RCCKBRECE1MUS81 | |
| SCHEMBL30683162 | 0.92 | GLP1R (0.81) | GLP1RPTH1RCCKBRECE1MUS81 | |
| SCHEMBL30148541 | 0.92 | NR3C1 (0.74) | GLP1RPTH1RCCKBRECE1MUS81 | |
| SCHEMBL31396476 | 0.92 | PTH1R (0.74) | GLP1RPTH1RCCKBRECE1MUS81 | |
| SCHEMBL30744278 | 0.91 | GRPR (0.69) | GLP1RPTH1RCCKBRGRPRECE1 | |
| SCHEMBL30008333 | 0.91 | PTH1R (0.66) | GLP1RPTH1RCCKBRGRPRECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129044-B1 | PEPTIDOGLYCAN HYDROLASE FOR USE IN THE TREATMENT OF CHRONIC BACTERIAL INFECTIONS | LYSANDO AG (LI) | 2022-09-07 | — | — | EP | claimed |
| WO-2025107024-A1 | TRANSGENIC INSECTS AND PREPARATIONS THEREOF | MACQUARIE UNIVERSITY (AU) | 2025-05-30 | — | — | WO | disclosed |
| WO-2024113002-A1 | TRANSGENIC INSECTS AND PREPARATIONS THEREOF | MACQUARIE UNIVERSITY (AU) | 2024-06-06 | — | — | WO | disclosed |
| US-11958890-B2 | Antimicrobial proteins | LYSANDO AG (LI) | 2024-04-16 | — | — | US | disclosed |
| US-20240099281-A1 | TRANSGENIC ANIMALS AND PREPARATIONS THEREOF FOR BIOREMEDIATION | MACQUARIE UNIVERSITY (AU) | 2024-03-28 | — | — | US | disclosed |
| US-11866750-B2 | Endolysin variant | SASINAPAS CO., LTD. (TH) | 2024-01-09 | — | — | US | disclosed |
| CN-109072211-B | Antibacterial agent against salmonella | 莱桑多股份公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3409685-B1 | INSOLUBLE FUSION PROTEIN COMPRISING ANTIMICROBIAL PEPTIDE AND METHOD FOR PRODUCING ANTIMICROBIAL PEPTIDE USING SAME | UNIV KONKUK IND COOP CORP (KR) | 2023-04-05 | — | — | EP | disclosed |
| EP-3129044-B1 | PEPTIDOGLYCAN HYDROLASE FOR USE IN THE TREATMENT OF CHRONIC BACTERIAL INFECTIONS | LYSANDO AG (LI) | 2022-09-07 | — | — | EP | disclosed |
| US-11427812-B2 | Antimicrobial agents against Staphylococcus aureus | LYSANDO AG (LI) | 2022-08-30 | — | — | US | disclosed |
| WO-2022126177-A1 | TRANSGENIC ANIMALS AND PREPARATIONS THEREOF FOR BIOREMDIATION | MACQUARIE UNIVERSITY (AU) | 2022-06-23 | — | — | WO | disclosed |
| EP-3978605-A1 | ANTIMICROBIAL AGENTS AGAINST SALMONELLA BACTERIA | Lysando AG (LI) | 2022-04-06 | — | — | EP | disclosed |
| EP-3541406-B1 | NEW ANTIMICROBIAL AGENTS AGAINST STAPHYLOCOCCUS AUREUS | LYSANDO AG (LI) | 2022-03-16 | — | — | EP | disclosed |
| US-20220064623-A1 | ENDOLYSIN VARIANT | SASINAPAS CO., LTD. (TH) | 2022-03-03 | — | — | US | disclosed |